AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic

NNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S, a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
2011 CMHS Uniform Reporting System (URS) Output Tables for Washington

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
National Survey on Drug Use and Health (NSDUH-2011)

<p>The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2011 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.</p>
Compound 525733: (p-Methylbenzylidene)-propyl-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-methylphenyl)-N-propylmethanimine. Molecular Formula: C11H15N. Molecular Weight: 161.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528729: Adrenaline, DTFMB-TBDMS

Chemical compound data from PubChem database. IUPAC Name: N-[2-[3,4-bis[[tert-butyl(dimethyl)silyl]oxy]phenyl]-2-[tert-butyl(dimethyl)silyl]oxyethyl]-N-methyl-3,5-bis(trifluoromethyl)benzamide. Molecular Formula: C36H57F6NO4Si3. Molecular Weight: 766.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401079-T1: [Translated] THE USE OF C-KITE INHIBITORS TO TREAT AUTOIMMUNE DISEASES

The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Chron's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft-versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly on-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
COVID-19 State Profile Report - Oklahoma

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Characteristics of High and Low Efficiency Hospitals

We compared performance, operating characteristics, and market environments of low- and high-efficiency hospitals in the 37 states that supplied data to the Healthcare Cost and Utilization Project from 2006 to 2010. Hospital cost-inefficiency estimates using stochastic frontier analysis were generated. Hospitals were then grouped into the 100 most- and 100 least-efficient hospitals for subsequent analysis. Compared with the least efficient hospitals, high-efficiency hospitals tended to have lower average costs, higher labor productivity, and higher profit margins. The most efficient hospitals tended to be nonteaching, investor-owned, and members of multihospital systems. Hospitals in the high-efficiency group were located in areas with lower health maintenance organization penetration and less competition, and they had a higher share of Medicaid and Medicare admissions. Results of the analysis suggest there are opportunities for public policies to support improved efficiency in the hospital sector.Characteristics of High and Low Efficiency Hospitals(link is external)
Table 15. Cigarette Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 15. Cigarette Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
HHS Data Governance Board Membership

The purpose of the U.S. Department of Health & Human Services (HHS) Data Governance Board (DGB) is to serve as the Department’s principal data governance forum and decision-making body for managing HHS’ data as a strategic asset and to support HHS in meeting its mission and agency priorities, including implementation of the Evidence Act.

The HHS DGB currently meets <b>monthly</b> to support these activities.

This dataset serves to communicate to the public the members of the HHS DGB, as required by the Federal Data Strategy.
Lowering of lipid composition in aorta of guinea pigs by

Background
          A short-term study was carried out using guinea pigs to determine the effects of Curcuma domestica on lipid composition in the serum and aorta.
        
        
          Methods
          Animals were given food pellets containing 4% (w/w) powdered rhizome of C. domestica in order to determine its effect on cholesterol, triglyceride and phospholipid levels in the aorta and serum. The animals were fed either a cholesterol free diet or a high cholesterol diet (2% cholesterol, w/w, in food pellet) in order to induce hypercholesterolemia.. After five weeks of this diet treatment, blood and aorta were taken for biochemical analysis and histological studies.
        
        
          Results
          C. domestica in the diet showed no significant effect on the levels of cholesterol, triglyceride and phospholipid in the serum and aorta of the cholesterol free diet animals. However, addition of C. domestica to a high cholesterol diet counteracted increases in the levels of cholesterol, triglyceride and phospholipid in the aorta. Histology studies showed less cholesterol deposits in the aorta of high cholesterol diet animals given C. domestica compared to the high cholesterol diet animals not given C. domestica supplement. C. domestica also had a lowering effect on triglyceride level in the serum of high cholesterol diet animals but showed no effect on serum cholesterol and phospholipid levels.
        
        
          Conclusion
          This study has shown that dietary intake of C. domestica decreased all lipid composition levels in the aorta and also the serum triglyceride level. In addition, C. domestica also reduced cholesterol deposition in the aorta of high cholesterol diet animals.
Compound 527224: 1,4a-Dimethyl-7-propan-2-yl-2,3,4,5-tetrahydronaphthalen-1-ol

Chemical compound data from PubChem database. IUPAC Name: 1,4a-dimethyl-7-propan-2-yl-2,3,4,5-tetrahydronaphthalen-1-ol. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529129: n-Butyl(trimethyl)-N-(trimethylsilyl)silanamine

Chemical compound data from PubChem database. IUPAC Name: N,N-bis(trimethylsilyl)butan-1-amine. Molecular Formula: C10H27NSi2. Molecular Weight: 217.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530085: Neopentyl 4-cyanobenzoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(1-methylimidazol-4-yl)acetate. Molecular Formula: C9H16N2O2Si. Molecular Weight: 212.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Characterization of a multi-stage focusing nozzle for collection of spot samples for aerosol chemical analysis

Concentrated collection of aerosol particles on a substrate is essential for their chemical analysis using various microscopy and laser spectroscopic techniques. An impaction-based aerosol concentration system was developed for focused collection of particles using a multi-stage nozzle that consists of a succession of multiple smooth converging stages. Converging sections of the nozzle were designed to focus and concentrate a particle diameter range of 900 to 2500 nm into a relatively narrower particle beam to obtain particulate deposits with spot diameters of 0.5-1.56 mm. A slightly diverging section before the last contractions was included to allow for better focusing of particles at the lower end of the collectable diameter range. The characterization of this multi-stage nozzle and the impaction-based aerosol concentration system encompassing the nozzle was accomplished both numerically and experimentally. The numerical and experimental trends in collection efficiency and spot diameters agreed well qualitatively; however, the quantitative agreement between numerical and experimental results for wall losses was poor, particularly for larger particle diameters. The resulting concentrated particulate deposit, a spot sample, was analysed using Raman spectroscopy to probe effect of spot size on analytical sensitivity of measurement. The method’s sensitivity was compared against other conventional techniques, such as filtration and aerosol focused impaction, implementing condensational growth.  Impaction encompassing the multi-stage focusing nozzle is the only method that can ensure high sensitivity at Reynolds numbers greater than 2000, that can be supported by small pumps which renders such method suitable for portable instrumentation.
Compound 525834: N,N-Dimethyl-N'-(4-nitrophenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(4-nitrophenyl)propanimidamide. Molecular Formula: C11H15N3O2. Molecular Weight: 221.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Influenza Surveillance Weekly - Historical

NOTE: This dataset is no longer being updated but is being kept for historical reference. For current data on respiratory illness visits and respiratory laboratory testing data please see <a href="https://data.cityofchicago.org/Health-Human-Services/Influenza-COVID-19-RSV-and-Other-Respiratory-Virus/qgdz-d5m4">Influenza, COVID-19, RSV, and Other Respiratory Virus Laboratory Surveillance</a> and <a href="https://data.cityofchicago.org/en/Health-Human-Services/Inpatient-Emergency-Department-and-Outpatient-Visi/7ce8-bpr6">Inpatient, Emergency Department, and Outpatient Visits for Respiratory Illnesses</a>. 

This dataset includes aggregated weekly metrics of the surveillance indicators that the Department of Public Health uses to monitor influenza activity in Chicago. These indicators include:

- Influenza-associated ICU hospitalizations for Chicago residents, which is a reportable condition in Illinois (HOSP_ columns)

- Influenza laboratory data provided by participating sentinel laboratories in Chicago (LAB_ columns)

- Influenza-like illness data for outpatient clinic visits and emergency department visits.  (ILI_ columns)

For more information on ILINET, see https://www.cdc.gov/flu/weekly/overview.htm#anchor_1539281266932.

For more information on ESSENCE, see https://www.dph.illinois.gov/data-statistics/syndromic-surveillance

All data are provisional and subject to change. Information is updated as additional details are received.  At any given time, this dataset reflects data currently known to CDPH.  Numbers in this dataset may differ from other public sources.
Table 10. Binge Alcohol Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 10. Binge Alcohol Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
Compound 530716: o-Anisic acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl 2-methoxybenzoate. Molecular Formula: C18H22O3. Molecular Weight: 286.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: Region 9, Volume 7

Explore state and regional data for HHS Region 9 with this user-friendly behavioral health report. It uses data from the 2021-2022 National Surveys on Drug Use and Health (NSDUH). The topics addressed in this report include substance use, substance use disorders, and mental health. Selected estimates are provided for adolescents aged 12 to 17, underage people aged 12 to 20, adults aged 18 or older, and the general population aged 12 or older. Statistical tests compare population percentages of (1) HHS region versus national estimates, (2) state versus national estimates, and (3) state versus HHS region estimates.
Compound 525827: N,N-Dimethyl-N'-(3-methylphenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(3-methylphenyl)propanimidamide. Molecular Formula: C12H18N2. Molecular Weight: 190.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD iMAP: Maryland Long Term Care Assisted Living - Assisted Living

This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. OP&R organizes and prepares for public health and medical emergencies through statewide partnerships with public -  private and government agencies to coordinate an effective emergency response for the health and safety of all residents of Maryland. Last Updated:  10/06/2014 Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_LongTermCareAssistedLiving/FeatureServer/5 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patient and health service delay in the diagnosis of pulmonary tuberculosis in Ethiopia

Background
          Delay in the diagnosis of tuberculosis may worsen the disease, increase the risk of death and enhance tuberculosis transmission in the community. This study aims to determine the length of delay between the onset of symptoms and patients first visit to health care (patient delay), and the length of delay between health care visit and the diagnosis of tuberculosis (health service delay).
        
        
          Methods
          A cross sectional survey that included all the public health centres was conducted in Addis Ababa from August 1 to December 31 1998. Patients were interviewed on the same day of diagnosis using structured questionnaire.
        
        
          Results
          700 pulmonary TB patients were studied. The median patient delay was 60 days and mean 78.2 days. There was no significant difference in socio-demographic factors in those who delayed and came earlier among smear positives. However, there was a significant difference in distance from home to health institute and knowledge about TB treatment among the smear negatives. The health service delay was low (median 6 days; mean 9.5 days) delay was significantly lower in smear positives compared to smear negatives. Longer health service delay (delay more than 15 days) was associated with far distance.
        
        
          Conclusions
          The time before diagnosis in TB patients was long and appears to be associated with patient inadequate knowledge of TB treatment and distance to the health centre. Further decentralization of TB services, the use of some components of active case finding, and raising public awareness of the disease to increase service utilization are recommended.
Patent AT-E400186-T1: [Translated] SOLUBLE ROASTED CHICORY WITH HIGH INULIN CONTENT

Soluble roasted chicory powder with an inulin and fructooligosaccharide content above 40% (dry weight basis) is new.  An Independent claim is also included for a process for producing soluble roasted chicory powder, comprising drying fresh chicory roots, roasting the roots at 130  deg  C and low humidity, cooling and crushing the roots, extracting the chicory with hot water, and spray drying the extract.